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HDL, through sphingosine-1-phosphate (S1P), exerts direct cardioprotective eﬀects on ischemic myocardium. It remains un-
clear whether other HDL-associated sphingophospholipids have similar eﬀects. We therefore examined if HDL-associated sphin-
gosylphosphorylcholine (SPC) reduces infarct size in a mouse model of transient myocardial ischemia/reperfusion. Intravenously
administered SPC dose-dependently reduced infarct size after 30 minutes of myocardial ischemia and 24 hours reperfusion
compared to controls. Infarct size was also reduced by postischemic, therapeutical administrationofSPC. Immunohistochemistry
revealed reduced polymorphonuclear neutrophil recruitment to the infarcted area after SPC treatment, and apoptosis was
attenuated as measured by TUNEL. In vitro, SPC inhibited leukocyte adhesion to TNFα-activated endothelial cells and protected
rat neonatal cardiomyocytes from apoptosis. S1P3 was identiﬁed as the lysophospholipid receptor mediating the cardioprotection
by SPC, since its eﬀect was completely absent in S1P3-deﬁcient mice. We conclude that HDL-associated SPC directly protects
against myocardial reperfusion injury in vivo via the S1P3 receptor.
1.Introduction
High-density lipoproteins (HDL) exert beneﬁcial eﬀects on
cardiovascular pathologies not only due to their eﬀects
on reverse cholesterol transport, but in addition through
pleiotropic eﬀects on vessel wall biology [1]. In addition to
its eﬀects on vessel wall pathology, HDL has been shown
to protect from myocardial injury and necrosis during
reperfusion after ischemia [2]. Adhesion of leukocytes to the
vascular endothelium and subsequent transmigration are a
characteristic feature of inﬂammation. Reduced recruitment
of leukocytes during reperfusion after ischemic insult has
been shown to be beneﬁcial in numerous experimental
settings [3, 4]. Likewise, apoptotic cell death is a mainstay of
tissue damage secondary to reperfusion injury after transient
ischemia [5]. Antiapoptotic eﬀects have been demonstrated
to reduce reperfusion-induced tissue damage [6]. However,
there is an ongoing debate as to the causal role of apoptosis
in infarct enlargement during reperfusion injury.
We have recently demonstrated that high-density lipo-
proteins (HDL) protect from myocardial damage during
reperfusion after ischemia due to the anti-inﬂammatory and2 Mediators of Inﬂammation
antiapoptotic eﬀects of its sphingophospholipid (SPL)
component, sphingosine-1-phosphate [7]. Like S1P, sphin-
gosylphosphorylcholine (SP C )r e p r e s e n t sam a j o rS P L
species circulating with HDL. Several groups have shown
that SPC, similar to S1P, has an inhibitory eﬀect on TNF-α-
induced expression of cell adhesion molecules in endothelial
cells [8, 9]. SPL traveling with HDL have been shown
to induce vasodilatation in contracted vessels [2, 10, 11].
There is, however,evidencefordiﬀerentialandevenopposite
eﬀects when comparing S1P and SPC with respect to
their eﬀects in the cardiovascular system: S1P is a high-
aﬃnity ligand forthe S1P-receptorfamily while SPCrequires
much higher concentrations to activate these G-protein-
coupled receptors, which will activate NOS through Akt-
phosphorylation in both cases. In addition, there is evidence
for additional intracellular receptors or direct eﬀectors of
SPC and S1P. Engagement of these diﬀerent receptors could
indeed be a source for adverse eﬀects of SPC compared to
S1P.
We, therefore, tested the hypotheses that (i) SPC—like
S1P—exerts cardioprotective eﬀects in an in vivo mouse
model of myocardial ischemia with reperfusion and (ii)
that such cardioprotective eﬀects of SPC—if detectable—
are also mediated via S1P3 receptors to ultimately result in
reduced neutrophil recruitment and cardiomyocyte apop-
tosis to aﬀord protection from postischemic myocardial
necrosis.
2.MaterialandMethods
2.1. Materials. SPC and S1P (Sigma, Taufkirchen, Germany)
from methanol stock solutions were air dried and dissolved
in phosphate-buﬀered saline/1% bovine serum albumin and
administered intravenously in 100μl/10g body weight doses.
2.2. Myocardial Ischemia/Reperfusion. To assure strain inde-
pendent eﬀects of SPC treatment we used S1P3-deﬁcient
mice on a C57BL/6-background as well as an outbred Swiss
strain [12]. Animals were strain matched, age matched, and
sex matched and therefore used in a nonrandomized study
design. Myocardial ischemia was induced with the approval
of the Institutional Review Board and in accordance with the
Guide for the Care and Use of Laboratory Animals published
by the US National Institutes of Health as previously
published [7]. Brieﬂy, thoracotomy and ligation of the left
anterior descending coronary artery (LAD)at the level of the
left atrium were performed with silk-7-0 suture over a PE10-
tubing in barbiturate-anesthetized mice for 30 minutes. The
chest was closed before the animals were weaned from the
ventilator and extubated. After 24 hours of reperfusion,
animals were reanesthetized and perfused with 0.9% saline
through the abdominal aorta. The coronary ligation was
retied. 2% coomassie blue solution was injected to delineate
the area at risk. The heart was sectioned into 5 equal slices
from the apex to the base and immersed in 2-, 3-, 5-
triphenyltetrazolium chloride (TTC) solution at 37◦C. TTC
development lasted 10 minutes before the sections were
scanned, processed, and morphometrically analyzed for left
ventricular area, area at risk, and area of infarction using
Image J (NIH, Bethesda). Data are presented as the average
percent infarct size per area at risk. SPC (0.625, 1.25, and
2.5μg/g body weight) was administered either 30 minutes
before transient coronary ligation or therapeutically after
myocardial ischemia with reinstitution of reperfusion (SPC;
1,25μg/g body weight).
2.3. Immunohistochemistry. Perfusion-ﬁxed (4% paraform-
aldehyde), paraﬃn-embedded sections of SPC-pretreated
animals were stained for polymorphonuclear leucocytes
(PMN) using the monoclonal antibody MCA771G (Serotec,
Oxford, England), developed with antirat peroxidase-
coupled secondary antibodies and DAB as a substrate (Vec-
torstain, DAKO, Germany). TUNEL assays were performed
using the ApopTag kit (Chemicon, Temecula, USA). The
number of stained cells was semiautomatically determined
on three sections per heart using morphometrical analy-
sis software (AnalySIS, M¨ unster, Germany). Apoptosis of
rat neonatal cardiomyocytes was induced by exposure to
hypoxic conditions (0.8% O2 in the medium) for 210min
followed by 150min of reoxygenation. SPC (10μM; Sigma,
Taufkirchen, Germany) was administered directly before
onset of hypoxia. Apoptosis was assessed by TUNEL using
the MEBSTAIN Apoptosis Kit II (MBL, Woburn, USA).
TUNEL-positive nuclei were counted and expressed as
TUNEL-positive/total nuclei.
2.4. Flow Chamber Studies. In vitro eﬀects of SPC on
endothelial adhesiveness for mouse PMNs was determined
using a parallel-plate ﬂow chamber model as described
in detail previously [7]. PMNs were isolated from bone
marrow of mice [13] and labeled using cell tracker green
(Molecular Probes, Leiden, Netherlands) before being per-
fused at100s−1 across TNFα-activated immortalized murine
endothelioma cells (fEnd.5). The number of cells with ﬁrm
adhesion was determined on pictures taken from 15 high-
power ﬁelds after 5 minutes of cell perfusion followed by
5m i n u t e so fb u ﬀer wash and captured on an UltraView
(Perkin Elmer, J¨ ugesheim, Germany) confocal scanning
microscope. Quantiﬁcation was performed using Image J
software.
2.5. Statistical Analysis. Data are presented as mean ± SEM.
Nonparametric Kruskal-Wallis testing followed by Dunnett’s
test was employed to identify signiﬁcant diﬀerences between
groups. Signiﬁcant diﬀerences were assumed at P<. 05
(InStat, GraphPad Inc., San Diego, USA).
3.Results
3.1. Sphingosylphosphorylcholine (SPC) Reduces Infarct Size
after Myocardial Ischemia and Reperfusion In Vivo. In wild-
type mice, left ventricular cross-sectional area was 13.9 ±
0.7mm2. Ligation of the LAD resulted in an ischemic area
of 7.6 ± 0.5mm2 (n = 11) constituting the area at risk. The
infarcted area measured 3.4 ± 0.4mm2 (n = 11). NeitherMediators of Inﬂammation 3
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Figure 1: SPC protects against myocardial ischemia/reperfusion
injury in vivo. SPC (0.625, 1.25 and 2.5μg/g body weight) and 1%
bovine serum albumin in PBS were injected intravenously 30
minutes before and after myocardial ischemia with reinstitution of
reperfusion. Infarct size, after MI/R as a function of area at risk is
r e d u c e di nS P Ct r e a t e dm i c e .
leftventriculararea norarea at risk were statistically diﬀerent
between treatment groups. The mortality after myocardial
ischemia with reperfusion was about 15% while adminis-
tration of vehicle control or SPC showed no inﬂuence on
the rate of mortality in the diﬀerent treatment groups. In
previous work, we showed that S1P 19 and 38ng/g body
weight does-dependently reduced infarct size [7]. Since the
Kd of S1P receptors for SPC is up to 40-fold higher than that
for S1P [14, 15], we administered SPC in an equipotent dose
range (0.625, 1.25, and 2.5μg/g body weight) 30min before
transient coronary artery ligation. Intravenous injection of
SPC resulted in a dose-dependent reduction of infarct size
by 23%, 36%, and 50%, respectively (n = 8,10,5, P<. 05;
Figure 1). Interestingly, when administered therapeutically
with reinstitution of reperfusion after myocardial ischemia
we also observed a reduction of infarct size by 40% for SPC
(1.25μg/gbw) compared to BSA treated controls (n = 6, P<
.05; Figure 1).
3.2. SPC Reduces Leukocyte Recruitment In Vitro and In
Vivo. Leukocyterecruitment playsa crucial rolein ischemia/
reperfusion damage. To test the eﬀect of SPC on leukocyte-
endothelialinteractions in vitro, we used a parallel-plate ﬂow
chamber model where mouse macrophages or PMN were
perfused over a conﬂuent monolayer of activated murine
endothelial cells (fEnd.5), and their adhesion was quantiﬁed.
Stimulation with TNFα increased ﬁrm adhesion of PMNs to
fEnd.5 by 296 ± 19% (61 ± 19PMNs/mm2 in unstimulated
versus 180 ± 35 in TNFα-stimulated cells, n = 8, P<
.001). Addition of 10μM SPC reduced adhesion to 133
± 28PMNs/mm2 in TNFα-stimulated cells (n = 6, P<
.05 versus TNFα-stimulated cells in absence of SPC; Fig-
ure 2(a)). In vivo, during myocardial ischemia/reperfusion,
PMN recruitment was decreased from 629 ± 45PMN/mm2
in vehicle-treated hearts to 332 ± 43PMN/mm2 in SPC-
pretreated hearts (n = 6/7, P<. 01; Figure 2(b)). The
observed antiadhesive eﬀect of SPC in vitro does not
prove a causal role of SPC on infarct size reduction
b u ts u g g e s t st h a ta n t i - i n ﬂ a m m a t o r ye ﬀects on endothelial
cells may add up to the composite cardioprotective eﬀect
in vivo.
3.3. SPC Protects Cardiomyocytes from Apoptosis In Vitro and
In Vivo. As S1P receptors are present and functional in
cardiomyocytes [16] and both HDL and lysophospholipids
are potent antiapoptotic signaling mediators in a number
of experimental systems [7, 17, 18], we tested if SPC
directly protects cardiomyocytes against apoptosis in vitro.
SPC had an antiapoptotic eﬀect as it signiﬁcantly reduced
the amount of TUNEL-positive nuclei after simulated
ischemia/reperfusion(8.7±0.6%versus6.5±0.9%TUNEL-
positive nuclei incontrol versusSPC treated cardiomyocytes,
n = 3, P<. 05; Figure 3(a)). In vivo, apoptotic cell death
was assessed in mice treated with SPC prior to ischemia.
TUNEL-staining in thearea at risk (outsidetheTTC-positive
area) was substantially reduced in lysophospholipid-treated
mice (920 ± 225 versus 643 ± 66 TUNEL-positive cells/mm2
in BSA versus SPC-treated mice, resp.; n = 5, P<. 01;
Figure 3(b)). By calculating the amount of apoptotic nuclei
per total nuclei in the area at risk (outside the TTC-positive
area) we estimated the amount of viable cardiac muscle
tissue lost due to apoptosis to be about 17% of the area at
risk.
3.4. Cardioprotective SPC Eﬀect Is Mediated by the S1P3
Lysophospholipid Receptor. In order to investigate which
S1P receptor mediates the cardioprotection of SPC, we
analyzed the eﬀects of SPC in knockout-S1P3 receptor mice
(S1P3
−/−) that were available only on the C57BL/6 back-
ground. Whereas the studies reported above were carried
o u ti na no u t b r e dS w i s ss t r a i n ,t h ec a r d i o p r o t e c t i o no fS P C
(1,25μg/gbw) is present to the same extent in wild-type
C57BL/6 mice (29 ± 3,8% versus 34 ± 2% infarction/area
at risk, C57BL/6 versus Swiss, n = 6, P<. 05; Figure 4).
However, in S1P3
−/−-mice no protection by SPC on infarct
size was detectable (105 ± 9% of vehicle-treated control,
n = 5, P = ns; Figure 4).
4.Discussion
The salient ﬁndings of this study are that HDL-associated
SPC, like S1P, exerts cardioprotective antiapoptotic and
anti-inﬂammatory eﬀects when administered preventively
prior to ischemia or therapeutically to ischemic myocardium
during reperfusion. This eﬀect is mediated through the S1P3
receptor and according to our previously published results
likely to be nitric oxide dependent.
Long-term beneﬁcial atheroprotective eﬀects of HDL are
generally accepted. Increasing evidence points to additional
eﬀects of HDL in connection with acute tissue ischemia
independentofitsrole as cholesterol acceptor.A recent study
demonstrated improved functional postischemic recovery of4 Mediators of Inﬂammation
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Figure 2: SPC inhibits PMN adhesion to activated endothelium
under ﬂow in vitro and PMN recruitment in the infarction area
in vivo.( a )P M Na d h e s i o nt oT N F - α-activated endothelial cells
in vitro in the presence and absence of 10μM SPC as quanti-
ﬁed in a parallel-plate ﬂow-chamber system. (b) Representative
immunohistochemistry and morphometric quantiﬁcation of PMN
in infarcts of vehicle- and SPC-treated mice, respectively, 24 hours
after ischemia/reperfusion.
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Figure 3: SPC inhibits apoptosis of cardiomyocytes in vitro and
in the infarction in vivo. (a) Quantiﬁcation of TUNEL-positive
nuclei in rat neonatal cardiomyocytes after simulated ischemia/
reperfusion in the presence or absence of 10μM SPC. (b) Represen-
tative terminal dUTP nick end-labeling (TUNEL) staining in the
area at risk (outside the TTC-positive area) of control and SPC-
treated mice 24 hours after ischemia/reperfusion. Morphometric
quantiﬁcation is presented above.
isolated rat hearts by HDL that was attributed to scavenging
of myocardially released TNFα by HDL [19]. Former studies
demonstrated a reduced leukocyte-endothelialinteraction in
connection with atheroprotection in vitro [20]a n din vivo
[21].Mediators of Inﬂammation 5
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Figure 4: The S1P3 lysophospholipid receptor is required for car-
dioprotection by SPC. Infarct size/area at risk was determined
in S1P3-deﬁcient mice and their matching wild-type controls
(C57BL/6) after treatment with SPC (1.25μg/g body weight).
Rapid reperfusion isanestablished priority for treatment
of myocardial ischemia. The underlying intention is to
minimize tissue destruction and thereby infarct size with
subsequent improved outcome of the patient. We have
shown that HDL, in addition to its eﬀects on reverse choles-
terol transport, stimulates NO release in human endothelial
cellsand inducesvasodilatation [2, 10]. According to the aim
of rapid reperfusion of an occluded vessel, this may account
fordirectbeneﬁcialeﬀectsof HDLon ischemic myocardium.
Scar size is, however, not only dependent on tissue loss
during ischemia, but increases due to the inﬂammatory
response during reperfusion [22]. Studies with isolated
perfused hearts argue against a signiﬁcant neutrophil-de-
pendent component in cardioprotection, since postcondi-
tioning reduced infarct size and necrosis in such leukocyte-
free models [23]. However, studies from our group showed
that three hours after ischemia, only a small part of the tissue
defectisduetoleukocyteswhereas 24hoursafterreperfusion
tissue loss is almost twice as big in controls compared to
leukocyte depleted animals [7], indicating that neutrophils
contributeimportantly to a second waveof myocardial tissue
loss during later phases. We can not, however, exclude some
degree of interdependence of inﬂammation and apoptosis.
That is, inﬂammatory cell recruitment may contribute to
cardiomyocyte apoptosis. One argument supporting this
notion is the earlier observation that antileukocyte strategies
can entirely prevent tissue damage occurring during later
phases of reperfusion [7].
We haverecentlyshown thatHDLreducescardiomyocyte
apoptosis and leukocyte recruitment to the postischemic
myocardium resulting in a cardioprotective eﬀect. This
eﬀect was mediated by HDL’s constituent sphingosine-1-
p h o s p h a t et h a ta c t st h r o u g hi t sr e c e p t o rS 1 P 3.T h eS 1 P 3
eﬀect, in turn, depends on nitric oxide synthase activity
[7]. In addition to S1P, sphingosylphosphorylcholine (SPC)
is another sphingophospholipid traveling with HDL, and
becauseoftheirdiverseaﬃnities todiﬀerentreceptorsubsets,
there is an ongoing debate whether SPC and S1P would exert
similar or antagonistic eﬀects in the cardiovascular system
[2, 24–26]. Furthermore, the distinct role of SPC in diﬀerent
cell types might be diverse. Nixon et al. [27] showed that
SPC administered to vascular smooth muscle cells acts as
a proinﬂammatory mediator. In contrast, we here show an
anti-inﬂammatory roleofSPCinendothelialcells,suggesting
that the balance between SPC eﬀects in diﬀerent cell types
mightbeanimportantfactor decidingifbeneﬁcialoradverse
eﬀects are realized in the cardiovascular system.
Multiple protein kinase and/or phosphatase-signaling
pathways are activated during ischemia with reperfusion
[23]. Eﬀects of SPC and S1P on downstream kinase
phosphorylation have been reported to be divergent in
vascular smooth muscle cells from rat cerebral arteries [28].
Therefore, we analyzed the phosphorylation of ERK1/2 and
p38MAPK in postischemic tissue and remote myocardium
in SPC- versus BSA-treated mice, but we did not observe
any signiﬁcant diﬀerences (data not shown). This ﬁnding
suggests that other signaling pathways might be involved in
the in vivo function of SPC.
We here demonstrate that the S1P3 lysophospholipid
receptor is required for cardioprotection by SPC, which is
somewhat surprising because SPC is known to have only
al o wa ﬃnity for S1P-receptors [14, 15]. Intracellular and
extracellular sphingosine kinases 1 and 2 convert SPC to
S1P, which could explain biological similarities of SPC and
S1P. While ischemia induces the formation of ceramide and
sphingosine by activation of sphingomyelinase, which have
been shown to reveal negative eﬀects on cardiac function,
it is likely that a rapid and eﬀective conversion of sphingo-
sylphosphorylcholine to S1P catalyzed by sphingosine kinase
[24] might be the underlying eﬀect of cardioprotection by
SPC.
Activation of sphingosine kinase (SphK) has been shown
to play a crucial role in protection against apoptosis in
oligodendrocyte survival by neutrophin-3 [29]. Further-
more, Jin and Karliner [30] reported cardioprotection via a
PKCepsilon-SphK-S1P-Akt pathway.
We can not exclude that SPC pretreatments sets of
cascades are also involved in preconditioning phenomena,
especially since nitric oxide seems to be one of the active
motifs. The postischemic treatment eﬀects that we observed
do not likewise exclude that postconditioning eﬀects are
accountable.Nevertheless,thereisan antiapoptoticand anti-
inﬂammatory eﬀect involved in SPC-fostered cardioprotec-
tion.
5.Conclusion
In aggregate, our data suggest that SPC, like S1P, exerts
cardioprotective eﬀects during reperfusion injury regardless
of the timing of its administration. Even if HDL rising
strategies would, in parallel, increase circulating bioactive
S1PalongwithSPC,noadverseeﬀectsofSPCwillantagonize
S1Ps beneﬁcial eﬀects. The perspectives of interventions
designed to acutely raise HDL levels in patients at high risk,
forexample,suchwithacutecoronary syndromes toimprove
prognosis may be very attractive both for patients and
clinicians.6 Mediators of Inﬂammation
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